UNITED THERAPEUTICS CORPORATION (UTHR)

Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $648.33. ... NASDAQ:UTHR opened at $517.71 on Friday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a market cap …

LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.

United Therapeutics (UTHR) stock is in focus after the company reported statistically significant phase 3 ADVANCE OUTCOMES results for its investigational PAH therapy ralinepag, with full data recently published in The Lancet. See our latest analysis for United Therapeutics.

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), sold 9,500 shares of the company’s common stock on July 29, 2026, for a total value of $4,962,487. The shares were sold at prices ranging from $517.68 to $525.78 per share.

In the last quarter, insiders sold 502,833 shares of company stock worth $279,835,157. 8.60% of the stock is owned by company insiders. Shares of NASDAQ UTHR opened at $524.70 on Thursday. The firm has a market cap of $22.27 billion, a P/E ratio of 19.37, a price-to-earnings-growth ratio of ...